Novavax (NVAX)
(Delayed Data from NSDQ)
$14.94 USD
+1.09 (7.87%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $14.83 -0.11 (-0.74%) 7:20 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.94 USD
+1.09 (7.87%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $14.83 -0.11 (-0.74%) 7:20 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Zacks News
Emergent BioSolutions Collaborates for Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.
3 MedTech Stocks to Rebound After Coronavirus-Led Recoil
by Sriparna Ghosal
As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.
5 Drug Makers to Gain From Coronavirus Outbreak
by Zacks Equity Research
Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.
Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work
by Kinjel Shah
President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.
Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
Dropbox, Groupon, QIAGEN, Zoom Video Communications and Novavax highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Dropbox, Groupon, QIAGEN, Zoom Video Communications and Novavax highlighted as Zacks Bull and Bear of the Day
5 Biotechs That Escaped the Coronavirus Onslaught Last Week
by Kinjel Shah
Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
3 Stocks Are Gaining Even as Coronavirus Creates Chaos
by Sreyoshi Mukherjee
While key players in the United States are struggling to cope, the coronavirus has been a boon for some.
Company News for Feb 27, 2020
by Zacks Equity Research
Companies In The News Are: NVAX,
The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax
4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large
by Zacks Equity Research
Healthcare companies are trying to find a cure and contain the coronavirus outbreak. This keeps the industry in focus
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $6.97, marking a -0.57% move from the previous day.
Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Novavax, Inc. (NVAX).
Coronavirus: How Fast to 100,000 Infected?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Coronavirus: Epidemic or Pandemic?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs
by Indrajit Bandyopadhyay
Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.
3 Biotech Stocks Likely to Gain as Coronavirus Spreads
by Zacks Equity Research
Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.
The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech
Company News for Jan 22, 2020
by Zacks Equity Research
Companies in the news are: NVAX, UBER, CSS, VIVE
Options Traders Expect Huge Moves in Novavax (NVAX) Stock
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Coronavirus Infects Wall Street: Stocks to Gain & Lose
by Tirthankar Chakraborty
While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.